Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Change in Accured Expenses (2016 - 2025)

Bio-Techne (TECH) has 17 years of Change in Accured Expenses data on record, last reported at -$6.0 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 172.92% year-over-year to -$6.0 million; the TTM value through Dec 2025 reached $7.3 million, down 56.61%, while the annual FY2025 figure was $15.4 million, 22.11% up from the prior year.
  • Change in Accured Expenses reached -$6.0 million in Q4 2025 per TECH's latest filing, down from -$2.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $27.6 million in Q1 2023 and bottomed at -$28.4 million in Q3 2022.
  • Average Change in Accured Expenses over 5 years is $1.0 million, with a median of $2.8 million recorded in 2022.
  • The widest YoY moves for Change in Accured Expenses: up 1136.26% in 2023, down 277.04% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $18.8 million in 2021, then tumbled by 126.15% to -$4.9 million in 2022, then soared by 67.18% to -$1.6 million in 2023, then soared by 610.37% to $8.2 million in 2024, then tumbled by 172.92% to -$6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$6.0 million in Q4 2025, -$2.1 million in Q3 2025, and $3.4 million in Q2 2025.